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Interaction of the Bovine Papillomavirus
E2 Protein with Brd4 Tethers the Viral
DNA to Host Mitotic Chromosomes
formation status of the cells (Law et al., 1981). To ensure
persistence in both infected and transformed cells, the
replicated viral episomes need to faithfully partition to
the nuclei of daughter cells during mitosis. Without a
mechanism to ensure the localization of the viral genome
Jianxin You,1 Jennie L. Croyle,1 Akiko Nishimura,1
Keiko Ozato,2 and Peter M. Howley1,*
1Department of Pathology
Harvard Medical School
Boston, Massachusetts 02115
within the nuclear envelope following nuclear reassem-2 Laboratory of Molecular Growth Regulation
bly, the viral genome could be left behind in the cyto-National Institutes of Child Health and
plasm and lost either through degradation or dilutionHuman Development
after cell division.National Institutes of Health
Faithful partitioning of genetic materials between theBethesda, Maryland 20892
daughter cells during cell proliferation is vital for genomic
stability of all organisms. In eukaryotes, the centromere/
kinetochor complex is dedicated to faithfully separateSummary
replicated chromosomes into daughter cells. However,
the relatively small genomes of episomal DNA viruses,The papillomavirus E2 protein tethers viral genomes
such as PV, prevent them from sparing millions of baseto host mitotic chromosomes to ensure genome main-
pairs of DNA for centromere function during the hosttenance. We have identified the bromodomain protein
mitosis. Nonetheless, an adequate strategy was devel-Brd4 as a major cellular interacting partner of the bo-
oped by these viruses to colocalize with the chromo-vine papillomavirus E2. Brd4 associates with mitotic
somes through a noncovalent interaction.chromosomes and colocalizes with E2 on mitotic
Several groups have shown that the bovine papillo-chromosomes. The site of E2 binding maps to the
mavirus (BPV) E2 protein is a key player for long-termC-terminal domain of Brd4. Expression of this C-ter-
episomal maintenance of viral genomes within replicat-minal Brd4 domain functions in a dominant-negative
ing cells (Bastien and McBride, 2000; Ilves et al., 1999;manner to abrogate the colocalization of E2 with Brd4
Lehman and Botchan, 1998; Skiadopoulos and McBride,on mitotic chromosomes, to block association of the
1998). The first insight into this E2 function came fromviral episomes with Brd4, and to inhibit BPV-1 DNA-
the observations that E2 as well as BPV-1 episomes aremediated cellular transformation. Brd4 also associ-
closely associated with mitotic chromatin in dividingates with HPV16 E2, indicating that Brd4 binding may
cells (Ilves et al., 1999; Lehman and Botchan, 1998; Skia-be a shared property of all papillomavirus E2 proteins.
dopoulos and McBride, 1998). E2 plays a critical role inThe interaction of E2 with Brd4 is required to ensure
viral DNA replication by binding cooperatively with PVthe tethering of viral genomes to the host mitotic chro-
E1 protein to the viral origin (Howley and Lowy, 2001).mosomes for persistence of viral episomes in PV-
Although this interaction and the minimal origin of repli-infected cells.
cation are sufficient to support the transient replication
of viral plasmids, long-term maintenance of the viralIntroduction
episomes requires, in addition, a cis minichromosome
maintenance element (MME), which consists of multipleThe papillomaviruses (PVs) comprise a group of small
E2 binding sites (Piirsoo et al., 1996). In the presenceDNA viruses that induce benign lesions in a variety of
of E2 protein, the MME is attached to the mitotic chro-higher vertebrates, including humans. Certain human
mosomes. Furthermore, the chromatin attachment func-
papillomavirus (HPVs) such as HPV16 and 18 are also
tion correlates perfectly with the stable episomal main-
closely associated with the pathogenesis of cervical
tenance of the viral plasmids (Ilves et al., 1999). Taken
cancer and other human tumors (zur Hausen, 2002). The together, these studies strongly suggest that E2 facili-
PVs have a specific tropism for squamous epithelial cells tates viral genome segregation by interacting simultane-
and must infect cells within the dividing basal epithelial ously with condensed mitotic chromatin and viral ge-
cell layer to establish an infection. The life cycle of the nomes.
virus is intimately associated with the differentiation pro- However, very little is known about the cellular factors
gram of the squamous epithelial cell. Late gene expres- involved in the long-term maintenance of the PV ge-
sion, lytic DNA amplification, and viral production are nomes. It was shown that the DNA binding function
restricted to the more differentiated keratinocytes near of E2 is not necessary for its association with mitotic
the surface of the epithelium (Howley and Lowy, 2001). chromosomes (Skiadopoulos and McBride, 1998), there-
During latent infection period, the viral genomes are fore, the interaction of E2 with mitotic chromosomes
maintained as autonomous replicating extrachromo- cannot be mediated by E2 binding directly to cellular
somal elements (episomes) at a low copy number in DNA. A cellular protein has therefore been postulated to
the nuclei of proliferating host cells (Gilbert and Cohen, more likely link E2 to the cellular mitotic chromosomes.
1987). In BPV-1-transformed mouse cells, the viral ge- However, this cellular mitotic receptor has not yet
nomes also replicate as multicopy nuclear plasmids that been identified.
can persist over long periods of time to maintain trans- Utilizing a proteomic approach to systematically char-
acterize cellular proteins that associate with E2 in vivo,
we identified the human protein Brd4 (bromodomain-*Correspondence: peter_howley@hms.harvard.edu
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containing protein 4) as an E2-interacting protein. Brd4 the transactivation domain of the protein and consist
primarily of the C-terminal DNA binding/dimerization do-contains two bromodomains, which are conserved se-
main. Both E2TR and E8/E2 can inhibit the N-terminal-quence motifs that have been implicated in chromatin
dependent functions of E2TA through heterodimeriza-targeting. Little is known about the human Brd4 protein
tion with the full-length protein and competitive bindingor its mouse homolog, MCAP. Brd4 is a member of the
to its cognate DNA binding sites (Howley and Lowy,BET family proteins that carry two bromodomains, and
2001). Since we were particularly interested in furtherit associates with mitotic chromosomes (Dey et al.,
understanding the biological functions of E2 that have2000). It has recently been shown to bind to acetylated
been assigned to its N-terminal transactivation domain,chromatin with preferential binding for acetylated his-
we performed a comparative TAP analysis of E2TA andtone H4 (Dey et al., 2003). The human Brd4 gene is
the shorter E2TR.located on chromosome 19 and is the target of translo-
For stable expression of the E2 proteins, the HPV-cation t(15;19)(q13;p13.1), which defines a lethal upper
negative human cervical carcinoma C33A cell line, whichrespiratory tract carcinoma in young people (French et
carries a defective p53 and does not undergo cell cycleal., 2001). In addition, Brd4 has been shown to play an
arrest and apoptosis upon E2 expression (Desaintes etimportant role in cellular growth control and cell cycle
al., 1997), was transduced with a recombinant retrovirusprogression (Houzelstein et al., 2002; Maruyama et al.,
expressing a bicistronic mRNA encoding FLAG-HA-2002).
tagged E2 and an ILR2  subunit surface marker (IkuraIn this study, we show that Brd4 functions as the major
et al., 2000). The E2-expressing subpopulation of cellscellular receptor for E2 and viral genome on mitotic
was purified by repeated cycles of affinity sorting usingchromosomes. Blocking the E2/Brd4 interaction pre-
anti-ILR2 antibodies. E2s and their cellular interactingvented the mitotic chromosomal targeting of both E2
proteins were purified though two steps of immunoaffin-protein and the viral genome. In addition, blocking the
ity chromatography using immobilized FLAG and HAbinding of E2 to Brd4 inhibited transformation of mouse
antibodies, respectively. Proteins copurified with E2TA,C127 cells by cloned viral BPV-1 DNA. We demonstrated
but not E2TR, were identified by mass spectrometrythat Brd4 also associates with the HPV16 E2 protein,
analysis.indicating that interaction with Brd4 is not specific for
As demonstrated by previous studies (Ikura et al.,BPV-1 E2 and may be a general property of all PV E2 pro-
2000; Ogawa et al., 2002), one advantage of the TAPteins.
system that we employed here using retroviruses is that
the bait protein is expressed at a low to moderate level,Results
more comparable to the levels of endogenous cellular
proteins. Since it has been reported that the use of aIdentification of Brd4 as a BPV-1
strong promoter to overexpress E2 protein can result inE2-Interacting Protein
misfolding and disruption of E2 activity (Bastien andThe PV E2 protein plays critical roles in the viral life cycle,
McBride, 2000), we believe that this TAP system is par-regulating viral transcription, as an accessory factor for
ticularly suited for expression of E2 and affinity purifica-
DNA replication, and in ensuring plasmid maintenance.
tion of its natural interacting partners. Prior to the TAP
These diverse functions suggested that E2 might inter-
protein purification, we have demonstrated that the
act with a variety of different cellular partners. Although
FLAG-HA-tagged E2TA proteins stably expressed in
some cellular partners have already been identified in cells were functional in an E2 transactivation assay (data
the literature using the yeast two-hybrid system and not shown).
other biochemical approaches (Howley and Lowy, As shown in Figure 1B, comparison of proteins copuri-
2001), we decided to use a proteomic approach applying fied with E2TA and E2TR on SDS-PAGE gel identified
the tandem affinity purification (TAP) technology (Ikura major and minor high molecular weight protein bands
et al., 2000; Ogawa et al., 2002) to identify additional E2 uniquely present in the E2TA immunoprecipitation (IP)
in vivo interacting proteins. The PV E2 proteins are well sample. Mass spec analysis identifies both of these
conserved among different PV types and across spe- bands as the human Brd4 bromodomain protein. To
cies. The biological functions of E2 have been best stud- confirm the mass spec identification result, an antibody,
ied for the genital tract HPVs and for BPV-1(Howley and C-MCAP, which recognizes the C-terminal 14 amino
Lowy, 2001). In our study, we chose BPV-1 E2 as a bait acids of both human and mouse Brd4, was used to blot
protein trying to identify cellular E2-interacting proteins. the protein samples coimmunoprecipitated with E2TA
The full-length BPV-1 E2 protein (E2TA) consists of well- and E2TR after tandem FLAG and HA affinity purification
conserved N-terminal and C-terminal domains con- (Figure 1C). The Western blot detected a major band of
nected by a flexible hinge region (Figure 1A). The N 200 kDa and two shorter fragments present in sample
terminus features a transcriptional activation domain coimmunoprecipitated with E2TA but not with E2TR.
that functions in transcriptional activation, transcrip- This 200 kDa band is the expected full-length product
tional repression, ensuring plasmid partitioning, and in- of Brd4. We believed that the two shorter fragments
teracting with the viral E1 protein. The E2 C terminus may be proteolytic-cleavage products of Brd4 that con-
contains the DNA binding and dimerization domain tain the last 14 amino acid of the protein because similar
(Howley and Lowy, 2001). BPV-1 also encodes two bands were also detected by mass spec analysis in the
shorter E2 proteins, E2TR that initiates at an internal E2TA TAP sample (Figure 1B). This experiment con-
initiation codon within the E2 open reading frame (orf) firmed the specific interaction of human Brd4 protein
and E8/E2 that is expressed from a spliced mRNA fusing with E2TA and not with E2TR, thus demonstrating a
requirement for the E2 N-terminal transactivation do-the E8 and E2 orfs. Both of these shorter forms lack
Brd4 Is the Papillomavirus E2 Mitotic Receptor
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Figure 1. Identification of Brd4 as a Major
Cellular Interacting Partner of the BPV-1 E2
Protein
(A) FLAG-HA-tagged E2 constructs for stable
expression in C33A cells. Shown are the do-
main structures of BPV-1 E2TA and E2TR pro-
teins. (F  FLAG tag; H  HA tag).
(B) Proteomic analysis of cellular proteins that
associate with E2 in vivo. Nuclear lysates
from C33A/E2TA and C33A/E2TR stable cells
were immunoprecipitated with anti-FLAG M2
beads followed by anti-HA antibody-conju-
gated sepharose. Proteins copurified with
E2TA and E2TR were analyzed on SDS-PAGE
gel and stained with Coomassie blue. Molec-
ular weights of the markers are indicated on
the left. The identities of the marked bands
were obtained by MALDI-TOF mass spec-
trometry.
(C) Anti-Brd4 immunoblot of cellular proteins
coimmunoprecipitated with E2. An anti-Brd4
rabbit polyclonal antibody C-MCAP (recog-
nizes both human and mouse Brd4 protein)
was used to show that human Brd4 protein
is uniquely present in the sample coimmuno-
precipitated with E2TA after FLAG and HA
affinity purification.
main for this interaction. In a separate experiment in mitotic chromosomes (Figure 2). The overlay of the E2
and Brd4 immunofluorescent images demonstrated thatwhich C33A/E2TA and C33A/E2TR stable cells were
transiently transfected with FLAG-tagged mouse Brd4 these two proteins colocalized specifically on mitotic
chromosomes, where the green E2 staining (Figure 2B)gene, we also showed that ectopically expressed mouse
Brd4 also specifically interacted with E2TA and not with and the red Brd4 staining (Figure 2A) appeared as
merged bright yellow dots (Figure 2D). Therefore, E2TAE2TR (data not shown).
and Brd4 proteins colocalize on mitotic chromosomes.
The colocalization of E2 and Brd4 on metaphase chro-E2 and Brd4 Protein Colocalize on Human
Mitotic Chromosomes mosomes was also observed in BPV-1-transformed
C127 cells (data not shown).Previous work has shown that the transactivation do-
main of E2TA is necessary and sufficient for the associa- In contrast, staining of E2TR in stable C33A/E2TR cells
revealed diffuse localization throughout the nucleus intion of E2 with mitotic chromosomes (Bastien and
McBride, 2000). Since the transactivation domain was all cells. Furthermore, E2TR was excluded from mitotic
chromosomes in metaphase cells while Brd4 remainedalso critical for binding to Brd4, which binds to mitotic
chromosomes, we next analyzed the cellular localization associated with the mitotic chromosomes (Supplemen-
tal Figure S1 at http://www.cell.com/cgi/content/full/of Brd4 and E2 protein in cells.
As shown in Figure 2A, Brd4 protein was detected in 117/3/349/DC1). This result indicated that the colocali-
zation of E2TA with Brd4 in punctate dots on mitoticthe nucleus mainly as highly condensed dots. This same
dot localization was observed in C33A cells expressing chromosomes required the E2 transactivation domain.
In previous work, it has been demonstrated that E2TRE2TR or no E2 protein (data not shown). In contrast,
E2TA protein displayed a speckled pattern of staining and E8/E2, another E2 protein also lacking the transacti-
vation domain, do not associate with mitotic chromatinin some of the cells and remained diffuse in others.
However, in mitotic cells, similar patterns of punctate (Skiadopoulos and McBride, 1998). Thus the E2 trans-
activation domain is required for both the associationdots were observed for Brd4 and for E2 over condensed
Cell
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Figure 2. Colocalization of Brd4 and E2TA on
Mitotic Chromosomes
C33A/E2TA cells were double-stained with an
anti-Brd4 rabbit polyclonal antibody N-MCAP
and an anti-E2TA mouse monoclonal anti-
body IE4. The staining was detected by incu-
bation with a Alexa Fluor 594 goat anti-rabbit
IgG (A) and a Alexa Fluor 488 goat anti-mouse
IgG (B), respectively. Cells were also counter-
stained with DAPI to help identify nuclei and
mitotic chromosomes (C). Cells were exam-
ined under a Zeiss LSM 510 UV upright confo-
cal microscope and the images from (A)–(C)
were merged using a Zeiss LSM 510 software
as shown in (D). Colocalization of hBrd4 and
E2 protein was distinctly observed on mitotic
chromosomes as bright yellow dots (D).
of E2 with mitotic chromosomes and the interaction with To further define the E2 binding region within the
aa1047–1362 segment of Brd4, we subcloned the Brd4the Brd4 protein. These data indicated that Brd4 could
represent the docking site for E2 on mitotic chromo- cDNA encoding the C-terminal 315 amino acids and
expressed them as 100 aa fragments by TNT. Thesomes.
GST-E2TA binding analysis of these smaller fragments
mapped the E2 binding region to the C-terminal 139Cloning of Human Brd4 cDNA and Mapping
amino acids (aa1224–1362) of Brd4 (Figure 3C). Struc-of Its E2 Binding Domain
tural prediction analysis indicated that this C-terminalThe two bromodomains on the predicted human Brd4
139 aa region might have a coil-coil structure. In theseprotein serve as the potential mitotic chromosome bind-
binding experiments, we have shown that the interactioning sites. To identify the domain(s) of human Brd4 that
of Brd4 with E2TA in vitro is mediated by the C-terminaltether E2 protein onto mitotic chromosomes, we pro-
139 amino acids of Brd4 and the N-terminal transactiva-ceeded next to clone the previously unavailable human
tion domain of E2TA. The mapping of the E2 bindingBrd4 cDNA. All the human Brd4 EST clones available
domain to the Brd4 C-terminal region suggested a strat-from ATCC I.M.A.G.E. bank only partially covered the
egy to disrupt the binding between E2 and Brd4 in cellspredicted Brd4 cDNA (see Experimental Procedures).
in order to investigate the importance of this interactionTo map the E2 binding domain on Brd4 protein, frag-
to the biology of the virus.ments from human Brd4 covering different regions of
the protein (Figure 3A) were translated and labeled by
S35Met using in vitro transcription and translation (TNT). Transient Expression of the Brd4 C-Terminal
Domain Blocks E2/Brd4 Interaction In VivoEach Brd4 TNT fragment translated from identical
amount of DNA template was incubated with either GST- Based on our in vitro binding results, we next examined
whether the Brd4 C-terminal 1047–1362 domain (CTD)E2TA or GST-E2TR immobilized on glutathione resin.
After extensive washing, bound proteins were eluted could exert a dominant-negative effect on the E2/Brd4
interaction. We expressed the CTD of Brd4 fused to afrom GST-E2TA beads (Figure 3B, lane A) and GST-
E2TR beads (lane R) and compared with 30% of the SV40 nuclear localization signal in cells to test whether
it would disrupt Brd4 and E2 binding.input (Figure 3B, lane I). Since our previous in vivo IP
experiment had shown that the endogenous Brd4 bound C33A/E2TA cells were transfected with either a pcDNA4C
plasmid encoding His-Xpress-SV40NLS-hBrd4-1047-E2TA but not E2TR, the GST-E2TR fusion protein served
as a negative control for background binding. Only frag- 1362 (CTD) or empty vector (V). Forty-eight hours after
transfection, nuclear extracts were prepared and immu-ments that showed significantly increased signal in GST-
E2TA elution than that observed in either the 30% input noprecipitated with anti-FLAG antibody and Western
blots performed to detect E2, endogenous Brd4, andor the E2TR elution were identified as E2 binding posi-
tive. As shown in Figure 3B and summarized in Figure the transfected Brd4-CTD. Similar levels of E2TA were
observed in cells transfected with vector or the CTD3A, all fragments containing the C-terminal aa1047–1362
region bound specifically to E2TA, but not E2TR, demon- expression plasmid (Figure 4, lanes 5 and 6). Full-length
endogenous Brd4 protein (and its proteolytic-cleavagestrating that the E2 binding domain of Brd4 resided in
this 315 C-terminal amino acid segment. Using a recipro- products) was complexed with E2 in cells transfected
with empty vector (Figure 4, lane 1), but not in cellscal binding assay, we confirmed that the C-terminal 315
aa of Brd4 fused to GST could pull down E2TA synthe- transfected with the Brd4-CTD. Instead, the tagged
Brd4-CTD protein was detected in the immunoprecipi-sized in vitro, but not E2TR (data not shown).
Brd4 Is the Papillomavirus E2 Mitotic Receptor
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Figure 3. Mapping of E2 Binding Domain on the Human Brd4 Protein
(A) Diagrams of human Brd4 full-length protein and fragments used to map the E2 binding domain. The full-length Brd4 and each indicated
subfragment were translated and labeled by S35Met using in vitro transcription and translation (TNT). Their abilities to bind E2TA protein are
summarized on the right.
(B) In vitro binding of Brd4 to E2 protein. Each Brd4 TNT product was tested for E2 binding on GST-E2TA or GST-E2TR protein immobilized
on glutathione resin. Aliquots (10 l) of sample eluted from GST-E2TA (lanes A) and GST-E2TR (lanes R) were resolved by SDS-PAGE along
with 30% of the input sample (lanes I) and detected by autoradiography. Only the fragments that showed significantly increased signal in
lane A over lane I were identified as positive E2 binding samples, as summarized in (A). Shown are the representative gels for both E2 binding
positive and negative fragments.
(C) Finer mapping of the E2 binding region on Brd4. Smaller fragments spanning the C-terminal 315 amino acids of Brd4 were generated by
in vitro transcription and translation. Their binding to GST-E2 fusion was tested as in (B).
tated sample by the Brd4 antibody, which recognizes Stable Expression of the Brd4 C-Terminal Domain
Prevents E2 Localization to Mitotic Chromosomesthe last 14 amino acids of Brd4 protein. In addition,
an anti-Xpress antibody also detected the same CTD To further address the biological significance of E2/Brd4
binding, we next tested whether disruption of the inter-protein coimmunoprecipitated with E2, confirming the
identity of the faster migrating band as the expressed action of E2 with Brd4 would affect E2 mitotic chromo-
some association. C33A/E2TA cells stably expressingHis-Xpress-SV40NLS-hBrd4-CTD product, and not a
proteolytic cleavage fragment of endogenous Brd4 Brd4-CTD or carrying an empty vector were established,
and the cells were double-stained with Brd4 and E2TAprotein.
These data confirmed the above in vitro mapping data antibodies and counterstained with DAPI. In the E2 cells
transduced by the vector alone, the red Brd4 stainingby showing that the aa1047–1362 fragment of Brd4,
when expressed in human cells, interacts with E2 pro- (Figure 4D) and the green E2 staining (Figure 4E) on
mitotic chromosomes overlapped completely in atein. Furthermore, these data established that Brd4 CTD
could function in a dominant-negative manner to com- merged image (data not shown), consistent with the
data presented in Figure 2 demonstrating the colocaliza-pete in the binding of E2 to endogenous Brd4 in vivo.
Cell
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Figure 4. Expression of the C-Terminal Do-
main of Brd4 in Cells Disrupts the Brd4 and
E2 Interaction and Prevents the Localization
of E2 Protein on Mitotic Chromosomes
(A) Anti-Brd4 immunoblot detection of the
competitive inhibition of Brd4 binding to E2
protein by a dominant-negative inhibitor.
C33A cells stably expressing the FLAG-HA-
E2TA protein were transiently transfected
with either a pcDNA4C plasmid express-
ing His-Xpress-SV40NLS-hBrd4-CTD or an
empty vector (V). Forty-eight hours after
transfection, nuclear extracts (NE) were pre-
pared from these cells and immunoprecipi-
tated with anti-FLAG M2 beads.
(B) Anti-Xpress immunoblot detection of the
interaction between E2 and the Brd4-CTD. In
cells expressing His-Xpress-SV40NLS-hBrd4-
CTD, the Brd4-CTD fragment was coimmuno-
precipitated with E2 by anti-FLAG beads.
(C) Anti-HA immunoblot detection of the im-
munoprecipitated E2 protein. The membrane
for immunoblot (A) was stripped and re-blot-
ted with an anti-HA peroxidase to demon-
strate that anti-FLAG immunoprecipitation of
E2 was not affected by the Brd4-CTD.
(D–I) C33A/E2TA cells stably expressing
Brd4-CTD (G–I) or carrying an empty vector
(D–F) were double-stained with an anti-Brd4
antibody (D and G) and an anti-BPV-1 E2 anti-
body (E and H). The anti-Brd4 antibody is
directed to the N terminus of the protein and
therefore does not recognize the Brd4-CTD.
Cells were also counterstained with DAPI to
label the nucleus and mitotic chromosomes
(F and I).
tion of E2 and Brd4 as punctate dots on the mitotic 5A). To test this model, we examined whether Brd4 was
associated with BPV-1 DNA and if the interaction de-chromosomes. However, in cells stably expressing
Brd4-CTD, E2 staining was completely excluded from pended upon the presence of E2 by chromatin immuno-
precipitation (ChIP) analysis.mitotic chromosomes (panel H), whereas Brd4 remained
in the dots on mitotic chromosomes (panels G–I). These C127ClH2 cells are BPV-1-transformed C127 cells
that carry BPV-1 DNA exclusively as episomes (C. Baker,patterns of staining were observed in 16 of 16 sets of
mitotic chromosomes in C33A/E2TA  vector cells and NCI, personal communication). These cells were trans-
duced with retroviruses expressing the dominant-nega-in 17 of 18 sets of mitotic chromosomes from C33A/
E2TA CTD cells. The one C33A/E2TA CTD cell line tive inhibitor His-Xpress-SV40NLS-hBrd4-CTD or vector
alone to generate stable cell lines H2-CTD or H2-V. Chro-in which no CTD effect was noted is likely due to the
lack of CTD expression since we were able to demon- matin prepared from C127, C127ClH2, H2-V, and H2-
CTD cells was assayed by ChIP using a Brd4 antibodystrate CTD expression in only 95% of the C33A/
E2TACTD cells. This result demonstrated that disrup- to an N-terminal segment of Brd4 that would recognize
tion of the E2/Brd4 interaction by Brd4-CTD prevented endogenous Brd4 but not the C-terminal domain. As
the tethering of E2 to host mitotic chromosomes. The controls for background binding, the Brd4 antibody was
direct correlation between E2/Brd4 binding and E2 mi- either omitted in the binding () or replaced by a control
totic chromosome localization demonstrated in this ex- nonimmune normal rabbit IgG. The presence of BPV-1
periment provides further support for the identification episomes in the DNA/protein complexes recovered was
of Brd4 as the E2 mitotic receptor. analyzed by PCR using primers that specifically amplify
a region of BPV-1 genome. As shown in Figure 5B, BPV-1
DNA could be detected in complex with Brd4 in H2-VDisruption of E2/Brd4 Interaction Abrogates
cells with the Brd4 antibody at levels significantly aboveTethering of BPV-1 Genome onto Brd4
the background signals seen with no antibody () orAs the E2 mitotic chromosome receptor, Brd4 would
with normal rabbit IgG. Similar ChIP results were alsoprovide the cellular docking site for BPV-1 episomes to
tether onto mitotic chromosomes through E2 (Figure obtained using the nontransduced C127Cl H2 cells (data
Brd4 Is the Papillomavirus E2 Mitotic Receptor
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Figure 5. Stable Expression of the Brd4
C-Terminal Domain Abrogates Association of
BPV-1 Genome with Brd4
(A) Proposed model for Brd4 as the receptor
for papillomavirus E2/DNA complex on mi-
totic chromosomes. The Brd4 CTD prevents
the association of Brd4 with E2, abrogating
the docking of E2 protein onto mitotic chro-
mosomes and disrupting the tethering of the
viral DNA to the chromosome by the Brd4
protein.
(B) Association of Brd4 with BPV-1 DNA in
C127ClH2 cells. C127ClH2 cells were trans-
duced with a CTD retrovirus or an empty vec-
tor retrovirus. Transduced cells were then se-
lected for 4 days in puromycin. Crosslinked
chromatin from C127, H2-V, and H2-CTD
cells was precipitated using antibody specific
to an N-terminal domain of Brd4 (Brd4), nor-
mal rabbit IgG (IgG), or without any antibody
() as a negative control. For the “mock”
chromatin IP, IP buffer was used instead of
chromatin. The recovered DNA was tested by
PCR using primers that specifically amplify a
region of BPV-1 genome. For lane 5, the input
chromatin from each cell line was tested in
parallel with the immunoprecipitated DNA.
Shown is the image of an agarose gel stained
with ethidium bromide.
not shown). The PCR product was not seen in the Furthermore, quantitative analysis of viral episome lev-
els in CTD-expressing H2 cells revealed a progressive“mock” ChIP, where the chromatin input was replaced
with ChIP buffer, nor was it detected in nontransformed loss of BPV-1 DNA with cell passage (data not shown).
C127 cells, which do not harbor BPV-1 episomes, indi-
cating that it is specific for the BPV-1 genome. Signifi- Blocking E2/Brd4 Interaction Inhibits BPV-1
Transformation of C127 Cellscantly, in the H2-CTD cells, the amount of Brd4 chroma-
tin-associated BPV DNA, as detected by the PCR, was In BPV-1-transformed mouse C127 cells, the viral ge-
nome is maintained stably in an extrachromosomal statereduced to nearly background level. Using a standard
curve to quantitate the relative amounts of DNA in the (Law et al., 1981). Since BPV-1 ably transforms C127
cells, we reasoned that blocking the tethering of thesamples, we estimate a 95% reduction in BPV-1DNA
levels in H2-CTD compared to HT-V cells. Furthermore, viral DNA to the mitotic chromosomes should result in
a loss of the viral DNA and a decrease in the efficiencyusing fluorescence in situ hybridization (FISH), we were
able to show that the BPV-1 episomes that were readily of transformation. We therefore generated C127 cells
that stably expressed the Brd4-CTD using retrovirusdetected associated with mitotic chromosomes in the
H2-V cells were undetectable in the H2-CTD cells (data transduction as well as vector control cells and tested
their respective susceptibilities to BPV-1 transforma-not shown). These results provide direct evidence that
Brd4 is associated with BPV-1 DNA in cells that stably tion. Stable expression of the Brd4-CTD was verified in
the C127 cells by immunofluorescent staining; further-maintain viral episomes. By blocking the E2/Brd4 inter-
action using the Brd4-CTD, we could specifically disrupt more, no differences were noted in the appearance or
growth parameters between Brd4-CTD-expressing cellsthe association of BPV-1 genome to Brd4, confirming
that the Brd4-episome interaction is mediated by E2. and vector control cells or nontransduced C127 cells
Cell
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Figure 6. Stable Expression of the Brd4 C-Terminal Domain Inhib-
ited BPV-1 Viral Genome-Induced Transformation of Mouse C127
Cells
Mouse C127 cells were infected with retrovirus to generate cells
stably expressing His-Xpress-SV40NLS-HBrd4-CTD (C127CTD) or Figure 7. Brd4 Interacts with HPV16 E2
carrying an empty vector as a control (C127V). C127 and the stable
(A) Anti-Brd4 immunoblot analysis of anti-FLAG-16E2 immunopre-
cells were each transfected with 1 g of BPV-1 DNA that has been
cipitation. C33A cells were transfected with FLAG-16E2 plasmid
purified after BamHI digestion of the p142-6 plasmid in which the
(F16) or an empty vector (). Cytoplasmic extracts (CE) and nuclear
full-length BPV-1 genome is cloned into pML2 at the BamH1 site.
extracts (NE) immunoprecipitated with anti-FLAG M2 beads were
After 21 days, the cells were fixed, stained with methylene blue, and
immunoblotted with the Brd4 antibody C-MCAP.
the number of transformed foci determined, as shown in (A). The
(B) Anti-FLAG immunoblot of M2 immunoprecipitation. Anti-FLAG
results from three independent transfections into each cell line are
immunoprecipitates from (A) were also immunoblotted with an anti-
summarized in (B).
FLAG antibody to detect the FLAG-tagged HPV16E2.
(C) Anti-16E2 immunoblot of M2 immunoprecipitation. Membrane
for immunoblot (B) was striped and reblotted with an anti-16E2
antibody to detect the presence of 16E2 protein.(data not shown). As shown in Figure 6, a comparable
level of transformation assayed by focus formation was
seen in the vector control cells and normal C127 cells.
and anti-16E2 immunoblots showed the IP of the HPV16In contrast, the numbers of colonies observed in the
E2 protein only in cells transfected with FLAG-16E2 plas-Brd4-CTD-expressing cells were decreased more than
mid (Figures 7B and 7C, respectively). This result90%. This decrease in transformation efficiency sug-
showed that Brd4 protein was coimmunoprecipitatedgests that the E2/Brd4 interaction could represent an
from the nuclear extract with 16E2, demonstrating thatexcellent target for developing antiviral inhibitors.
the interaction between Brd4 and BPV-1 E2 also applies
to other PV E2 proteins.
Brd4 Interacts with HPV16 E2 Protein
To determine whether Brd4 might serve as the tether
for other PV E2 proteins, we tested if the HPV16 E2 also Discussion
interacted with Brd4. C33A cells were transfected with
pCMV4-FLAG-16E2 or vector. Cytoplasmic and nuclear Some DNA viruses, like the PVs and the lymphotropic
herpesviruses, which establish persistent or latent infec-extracts prepared from these cells were subjected to
anti-FLAG IP to pull down the HPV16 E2 protein and tions, must be able to maintain their genomes as stable
episomes in the nuclei of infected cells. Although elabo-associated factors. A Brd4 immunoblot showed that the
Brd4 protein and its proteolytic-cleavage products rate mechanisms have been demonstrated for the effec-
tive segregation of low copy number plasmids in pro-coimmunoprecipitated with E2 using anti-FLAG beads
only in the nuclear extract of cells that were transfected karyotes (Niki and Hiraga, 1997; Nordstrom and Austin,
1989), the mechanisms by which eukaryotic episomalwith FLAG-16E2 plasmid (Figure 7A, lane 4). The set of
bands corresponding to Brd4 protein and its proteolytic- viruses ensure genome maintenance have not been yet
fully elaborated.cleavage products were not detected in C33A cells
transfected with the empty vector plasmid (lane 3), nor A major obstacle for maintaining plasmids in eukary-
otes is presented by the breakdown and reassembly ofwere they present in the cytoplasmic IP. Both anti-FLAG
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the nuclear membrane during cell division. Even high- instance, E2 was observed to localize diffusely in some
of the cells in which it was stably expressed and to becopy-number extrachromosomal viral genomes could
be excluded from the nucleus and subject to degrada- present in nuclear dots in others, raising the possibility
that E2 may be associated with Brd4 in some fractiontion in the cytoplasm if not tethered to the chromosomes
during mitosis. For the PVs, the consequence is the of cells that are not yet in mitosis. Additional insight into
the mechanisms involved in the regulation of the E2/very rapid and catastrophic loss of the viral genomes
(Lehman and Botchan, 1998). Noncovalent association Brd4 interaction awaits further investigation.
Association of viral genomes with host mitotic chro-with cellular chromosomes appears to be the principle
strategy employed by episomal DNA viruses to ensure mosomes via a viral encoded protein is a strategy em-
ployed by a number of different latent DNA viruses.that their genomes are enclosed within the new nuclear
envelopes and thus maintained in progeny cells (Bal- The EBNA1 protein of Epstein-Barr virus and latency-
associated nuclear antigen (LANA) of human herpesvi-lestas et al., 1999; Hung et al., 2001; Ilves et al., 1999;
Skiadopoulos and McBride, 1998). rus-8 are each required for stable viral genome mainte-
nance (Ballestas et al., 1999; Hung et al., 2001). LikeDuring the life cycle of the PVs, the viral genome is
maintained as an episome at a low copy level in the E2, each of these herpesvirus proteins is a sequence-
specific DNA binding protein that associates with mitoticinfected basal squamous epithelial cells (Howley and
Lowy, 2001). Therefore, a specific mechanism is neces- chromosomes (Ballestas et al., 1999; Hung et al., 2001).
Although several candidate chromosomal binding part-sary to ensure that the viral DNA is not lost from the
dividing basal cells of a papilloma. The E1 and E2 pro- ners have been identified for both EBNA1 and LANA
(Kapoor and Frappier, 2003; Shire et al., 1999; Cotterteins are sufficient for transient replication of viral ge-
nome containing the viral origin of replication; however, and Robertson, 1999; Krithivas et al., 2002; Platt et al.,
1999), none has been shown unequivocally to functionstable maintenance of origin-containing plasmids re-
quires E2 and regions from the viral long control region as their mitotic receptors.
We have demonstrated the direct interaction of Brd4(LCR) that contain E2-specific DNA binding sites (Piirsoo
et al., 1996). Previous work from several laboratories and the viral E2 protein and the colocalization of E2
with endogenous Brd4 on host mitotic chromosomes.has suggested that E2 binds to these sites and tethers
the viral genomes to mitotic chromosomes (Bastien and In addition, we developed the E2 binding domain of
Brd4, CTD, as a dominant-negative inhibitor to preventMcBride, 2000; Ilves et al., 1999; Lehman and Botchan,
1998; Skiadopoulos and McBride, 1998). E2 association with endogenous Brd4. Using the Brd4
CTD, we abolished both the mitotic chromosome asso-Our study identifies the bromodomain protein Brd4 as
the mitotic chromosomal receptor for E2. The interaction ciation of E2 protein and the tethering of BPV-1 DNA to
Brd4 (see Figure 5A). The direct mitotic chromosomebetween BPV-1 E2 and Brd4 was confirmed both in vivo
and in vitro. We mapped the E2 binding region of Brd4 association feature of Brd4 is further strengthened by
the demonstration that Brd4 selectively associates withto a 139 aa C-terminal domain. Brd4 interacts with the
N-terminal transactivation domain of E2, which has pre- acetylated histone H4 (Dey et al., 2000, 2003). These
in vivo data demonstrate that Brd4 represents the pre-viously been shown to be responsible for the colocaliza-
tion of E2 with Brd4 on mitotic chromosomes (Skiado- viously unidentified cellular factor that serves as the
receptor of E2/viral DNA complex on mitotic chromo-poulos and McBride, 1998). By ChIP and FISH analyses,
we show that Brd4 associates with extrachromosomal somes. By preincubation of recombinant E2TA protein
with the Brd4 CTD, we could prevent the association ofPV DNA in an E2-dependent manner. Our data thus
provide a molecular mechanism for E2-mediated plas- E2 with human mitotic chromosomes (data not shown).
Thus the region of the E2 transactivation domain tomid maintenance: mitotic chromosome-associated Brd4
interacts with the transactivation domain of E2, and the which Brd4-CTD binds is necessary for E2 association
with mitotic chromosomes and suggests that Brd4 mayC-terminal E2 DNA binding domain binds the viral DNA
through cognate E2 binding sites (Figure 5A). Through be the sole E2 mitotic receptor. Brd4 is thus the first
mitotic chromosome receptor to be identified for athese molecular interactions, the PV DNA becomes as-
sociated with host mitotic chromosomes before division DNA virus.
Although our studies have focused on the BPV-1, aof the sister chromatids.
To fulfill its viral genome maintenance function, E2 requirement for mitotic association of the viral DNA in
dividing cells is no doubt a general feature of all PVs,must tether the viral DNA to the condensed chromo-
somes early in mitosis and remain bound until after the including the HPVs (Howley and Lowy, 2001). Indeed
several cell lines derived from HPV16 and HPV31 pre-nuclear envelope has been reformed. To this end, E2
has been observed associated with condensed chromo- neoplastic lesions have been shown to harbor predomi-
nantly extrachromosomal viral DNA (Bedell et al., 1991;some at all stages of mitosis, at times when many other
transcription factors have been displaced from mitotic Stanley et al., 1989). Furthermore, replication assays
using HPV31 have shown roles for E2 and E2 bindingchromatin (Bastien and McBride, 2000). Brd4 associa-
tion with chromosomes through mitosis reveals a tem- sites in viral genome maintenance in cultured cells
(Hummel et al., 1992; Stubenrauch et al., 1998, 2000).poral pattern that coincides with the E2-chromosome
association (Dey et al., 2000). Although detailed studies on genome maintenance
functions for the HPVs have not yet been carried out, itThe colocalization of E2 with Brd4 was most distinctly
observed in mitotic cells, in which both proteins ap- seems likely that this E2 genome maintenance function
will be conserved among the PVs and that Brd4 maypeared in high-density punctate dots on mitotic chromo-
somes. However, at what stage of cell cycle E2 becomes serve as the mitotic receptor for E2 from different PVs.
In our studies, we have shown that HPV16 E2 proteinassociated with Brd4 remains an open question. For
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Tandem Affinity Purification of E2-Interacting Proteininteracts with endogenous Brd4, supporting the hypoth-
C33A cells stably expressing FLAG-HA-E2TA and E2TR were pre-esis that different PVs share a common pathway for
pared as described previously (Ikura et al., 2000; Ogawa et al., 2002).tethering to mitotic chromosomes through Brd4.
Nuclear extracts of C33A/E2TA and C33A/E2TR stable cells were
Using the Brd4 CTD, we have shown that disruption prepared as described (Groisman et al., 2003). The E2s and associ-
of E2/Brd4 binding can inhibit viral transformation, pre- ated components were isolated from nuclear extracts by IP with
anti-FLAG antibody followed by anti-HA antibody according tosumably by inhibiting the maintenance of the viral DNA
established procedure (Ikura et al., 2000; Ogawa et al., 2002). E2-in the infected cell. This observation suggests that E2/
associated protein bands were excised from SDS-PAGE gels, di-Brd4 binding could be a new target for the development
gested with trypsin, and analyzed by MALDI-TOF mass spectrome-of PV antivirals. Studies are underway to test if the Brd4
try for peptide sequence at the DFCI Molecular Biology Core Facility.
CTD can similarly disrupt the association between HPV
episome and host mitotic chromosomes. A minimum Immunoprecipitation and Western Blot Analysis
peptide region responsible for mediating the E2/Brd4 For transient protein expression, 40%–80% confluent cells growing
in 10 cm dishes were transfected with total 16 g of plasmid DNAinteraction could be used to design small molecules
using FuGENE 6 Transfection Reagent (Roche). Cells were har-and screen for compounds that could be useful in the
vested at 4872 hr after transfection. Cytoplasmic and nuclear ex-treatment or prevention of HPV infections and associ-
tracts were prepared as described previously (Schreiber et al., 1989).ated diseases.
For IP, soluble extract proteins were mixed with 10 l of anti-
FLAG M2 agarose (Sigma) and rotated at 4C for 4 hr. The beads
were washed three times with 1 ml 0.1 M KCl base buffer (20 mM
Experimental Procedures
Tris-HCl [pH 8.0], 10% glycerol, 5 mM MgCl2, 0.1% Tween 20, 0.1
M KCl, 0.2 mM PMSF, and 0.5 mM DTT), and bound proteins were
Recombinant Plasmid Construction
eluted with 30 l of sample buffer. Aliquots (10 l) were resolved
To construct retrovirus expression vectors for FLAG and HA epitope-
on a 10% gel. Proteins were transferred to Immobilon-P (Millipore)
tagged E2 proteins, E2TA and E2TR coding sequences were PCR
and blotted with specific antibody to detect the protein of interest
amplified and subcloned into pOZ-N vector using XhoI and NotI
(ECL detection). Antibodies employed in the Western blot analysis
sites (Ogawa et al., 2002). The resulting plasmids are pOZN-E2TA
were as follows: the rabbit polyclonal antibody against Brd4,
and pOZN-E2TR. Three I.M.A.G.E. Consortium clones spanning dif-
C-MCAP, has been described previously (Dey et al., 2000); the anti-
ferent regions of the human Brd4 cDNA were obtained from ATCC:
FLAG M2 monoclonal antibody was obtained from Sigma; the anti-
clone 5214463 (spanning nt. 1–1626), clone 4138081 (spanning nt.
Xpress mouse monoclonal antibody was from Invitrogen; the rabbit
1382–2161), and clone 380968 (spanning nt. 2601–4090). A 558 bp
polyclonal antibody against HPV16E2 has been described pre-
fragment spanning nt. 2133–2691 of human Brd4 cDNA missing in
viously (Sakai et al., 1996); and the anti-HA-Peroxidase was pur-
all of the available cDNA clones was isolated from a human cDNA
chased from Roche.
library (Panomics) by PCR. The cDNA fragments were appropriately
amplified by PCR and cloned into pGEX-6P-1 to construct a full-
Immunofluorescent Staininglength cDNA, which was then subcloned into pcDNA4C plasmid
C33A/E2TA stable cells were cultured on coverslips in DMEM con-using BamHI and NotI digestion. Fragments of human Brd4 cDNA
taining 10% fetal calf serum. Cells fixed with 3% paraformaldehydewere cloned into pcDNA3.1/V5-His using PCR and TOPO TA Expres-
were incubated for 10 min at room temperature in blocking/permea-sion Kit (Invitrogen) for expression controlled by both a CMV pro-
bilization buffer (0.5% Triton X-100 and 3% BSA in PBS) and stainedmoter and a T7 promoter. These plasmids were used for in vitro
with anti-Brd4 rabbit polyclonal antibody, N-MCAP ([Dey et al.,transcription and translation. To construct an expression plasmid
2000], 1/500 dilution), and an anti-BPVE2 mouse monoclonal anti-for the Brd4-CTD, the SV40 nuclear localization signal (NLS) was
body, 1E4 ([Kurg et al., 1999], 1/50 dilution) at room temperatureinserted in frame in front of the Brd4-CTD coding region by PCR
for 60 min. Cells were then washed three times with blocking/per-and the product was subcloned into pcDNA4C vector using BamHI
meabilization buffer and incubated for an additional 60 min using aand NotI sites. The resulting plasmid is pcDNA4C-His-Xpress-
Alexa Fluor 488 goat anti-mouse IgG (Molecular Probes, 1/500 dilu-SV40NLS-hBrd4-CTD. The His-Xpress-NLS-hBrd4-CTD cassette
tion) and a Alexa Fluor 594 goat anti-rabbit IgG (Molecular Probes,was reamplified by PCR and subcloned into pLPCX plasmid (BD
1/1000 dilution). Cells were counterstained with 0.3 M DAPI andBiosciences) to generate the pLPCX-His-Xpress-NLS-hBrd4-CTD
examined using either a Zeiss LSM 510 Meta UV upright confocalplasmid for stable cell line construction. pGEX-E2TA, pGEX-E2TR,
microscope and associated Zeiss LSM 510 software or a Leicaand pCMV-FLAG16E2 were from our laboratory plasmid bank. All
DMLB epifluorescence microscope equipped with a Leica DC 500plasmid constructs were verified by DNA sequencing.
digital camera.
In Vitro Binding of Brd4 to GST-E2Cells Culture and Cell Lines
S35Met-labeled Brd4 full-length protein or fragments were producedC33A and murine C127 cells were maintained as monolayers in
by in vitro transcription/translation in reticulocyte lysate (Promega)Dulbecco’s modified Eagle’s medium containing 10% fetal calf se-
using plasmids pcDNA3.1/V5-His carrying the human Brd4 full-rum. The BPV-1-transformed C127ClH2 cell line carrying extrachro-
length or partial cDNA, respectively. GST-E2TA and -E2TR fusionmosomal BPV-1 DNA was generously provided by Dr. Carl Baker
proteins were produced in E. coli using the respective pGEX plas-(NCI).
mids. A 20 l aliquot of each translation mixture was mixed with
5 l of immobilized GST-E2TA or GST-E2TR (1 g of protein/l
beads) and 0.18 ml PBS prior to 4 hr incubation at 4C. The beadsStable Cell Line Construction
were washed three times with 0.5 ml of 0.1 M KCl base buffer andUsing standard retrovirus production and transfection procedures,
eluted with 30 l of SDS-PAGE sample buffer. An aliquot of eachpOZN-E2TA and pOZN-E2TR plasmids were used to generate C33A
eluate (10 l) was analyzed by SDS-PAGE and autoradiography.cells stably expressing FLAG-HA-tagged E2TA and E2TR, desig-
nated C33A/E2TA and C33A/E2TR. To block the Brd4 and E2 inter-
action in C33A/E2TA and C127ClH2 cells, the pLPCX-His-Xpress- Chromatin Immunoprecipitation (ChIP)
Chromatin of C127, C127ClH2-V, or C127ClH2-CTD cells was pre-NLS-hBrd4-CTD plasmid was used to establish stable expression
of the Brd4 CTD. The resulting cell lines are C33A/E2TA-CTD and pared as described (Weinmann et al., 2001). Chromatin from 3 
107 cells was incubated with 5 g of either rabbit polyclonal anti-H2-CTD, respectively. As a control, retrovirus produced from pLPCX
empty vector was used to transduce the same parental cells to Brd4 antibody, N-MCAP (Dey et al., 2000), a control normal rabbit
IgG (Upstate), or no antibody at 4C for 12 hr. Recovery of immuneprepare stable cell lines carrying the vector backbone, C33A/E2TA-V
and H2-V, respectively. complexes and de-crosslinking of chromatin were carried out as
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described (Weinmann et al., 2001). After phenol/chloroform extrac- replication. In Fields Virology, D.M. Knipe and P.M. Howley, eds.
(Philadelphia, PA: Lippincott Williams & Wilkins), pp. 2197.tion and ethanol precipitation, DNA was resuspended in 30 l of
H2O and analyzed by PCR using primers specifically amplifying a Hummel, M., Hudson, J.B., and Laimins, L.A. (1992). Differentiation-
region of BPV-1 genome. induced and constitutive transcription of human papillomavirus type
PCR was performed using 2 l of IP or 2 l of a 1:300 dilution of 31b in cell lines containing viral episomes. J. Virol. 66, 6070–6080.
the total input chromatin in a 40 l reaction containing 0.4 M of
Hung, S.C., Kang, M.S., and Kieff, E. (2001). Maintenance of Epstein-each primer; 0.2 mM of dNTP; 1X Pfu polymerase buffer; and 2 U
Barr virus (EBV) oriP-based episomes requires EBV-encoded nu-of Pfu DNA polymerase (Stratagene). Following 30 cycles of amplifi-
clear antigen-1 chromosome-binding domains, which can be re-cation, the PCR products were separated on a 1.2% agarose gel and
placed by high-mobility group-I or histone H1. Proc. Natl. Acad. Sci.detected with ethidium bromide. The PCR primers were designed to
USA 98, 1865–1870.amplify 432 bp spanning nt. 2601–3032 of BPV-1 plasmid. Primer
Ikura, T., Ogryzko, V.V., Grigoriev, M., Groisman, R., Wang, J., Hori-sequences are available on request.
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